QMed, Inc. Reports First Quarter Results

EATONTOWN, N.J., April 18 /PRNewswire-FirstCall/ -- QMed, Inc. (NASDAQ:QMED) today announced financial results for the first quarter ending February 29, 2008. Revenue for the three-month period decreased to $751,788 from $1,728,676 in the prior year's quarter. Net loss for the quarter was $(999,184) or $(0.06) per share on a diluted basis, compared to net loss of $(1,057,776) or $(0.06) per share on a diluted basis, for the same period a year ago.

Income from discontinued operations of our managed care segment for the three-month period ended was $487,185 or $0.03 per share on a diluted basis, compared to a loss of $(1,447,795) or $(0.08) on a diluted basis the previous year. The income from discontinued operations reported within the first quarter of 2008 is primarily attributable to a non-cash reversal of approximately of $1.0 million related to the reduction in the Incurred But Not Reported and Paid liability and the corresponding medical expense.

Subsequent to February 29, 2008, the Company received a $375,000 secured loan for working capital and under certain conditions can receive an additional $375,000 as described in detail in the March 20, 2008 press release and in the notes to the Company's financial statements.

Given the continuing losses and the Company's current cash position available for working capital, the financial statements contain a disclosure about the Company's ability to continue as a going concern.

About QMed, Inc.

QMed has developed evidence-based clinical information management systems for use by health plan customers. The QMed systems incorporate Disease Management services to patients and decision support to physicians. The Company's subsidiaries have specialized in serving high-risk populations of Medicare beneficiaries.

Except for historical information contained herein, matters discussed in this news release are forward-looking statements that involve risks and uncertainties. They include but are not limited to those relating to the timely implementation of programs, the impact of competitive product introductions, acceptance and pricing, and those risks detailed in the Company's filings with the Securities and Exchange Commission (SEC). Actual results may differ materially from any forward-looking statements due to these risks and uncertainties.

    Contact:  William Schmitt, QMed, Inc. - 732-544-5544 x1112



                         QMED, INC. AND SUBSIDIARIES
                    CONDENSED CONSOLIDATED BALANCE SHEETS

                                                 February 29,     November 30,
                                                     2008            2007
    ASSETS                                       (unaudited)

    Current assets
    Cash and cash equivalents                 $     403,546    $   1,196,030
    Accounts receivable, net of allowances
     for doubtful accounts of $75,100 and
      $58,980, respectively                         399,639          535,810
    Prepaid professional fees                       203,000          228,000
    Prepaid expenses and other current
     assets                                         393,595          189,654
    Assets related to discontinued operations     4,644,835        6,126,492

                                                  6,044,615        8,275,986

    Property and equipment, net                     632,239          717,229
    Product software development costs, net       1,615,865        1,769,931
    Acquired intangibles, net                       379,773          421,224
    Other assets                                    135,123          137,190
                                              $   8,807,615    $  11,321,560

    LIABILITIES AND STOCKHOLDERS' EQUITY
    Current liabilities
    Accounts payable and accrued
     liabilities                              $   2,063,790    $   1,607,840
    Leases payable, current portion                  26,700           41,116
    Accrued salaries and commissions                191,025          245,888
    Fees reimbursable to health plans                20,050           12,900
    Contract billings in excess of revenues         197,380          197,380
    Income taxes payable                             11,353           12,786
    Liabilities related to discontinued           1,964,443        3,952,421
     operations
                                                  4,474,741        6,070,331

    Leases payable -- long term                      50,206           49,134
    Accrued severance payable, long term             12,410          309,258
                                                  4,537,357        6,428,723

    Commitments and Contingencies
    Stockholders' equity
       Common stock $.001 par value; 40,000,000
        shares authorized; 17,042,959 shares
         issued and 17,020,959 outstanding,
          respectively                               17,043           17,043
    Paid-in capital                              54,935,081       54,558,476
    Accumulated deficit                         (50,606,241)     (49,607,057)
                                                  4,345,883        4,968,462

    Less treasury stock at cost, 22,000
    common shares                                   (75,625)         (75,625)
    Total stockholders' equity                    4,270,258        4,892,837
                                              $   8,807,615    $  11,321,560




                         QMED, INC. AND SUBSIDIARIES
               CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                 (Unaudited)

                                                                  Restated
                                                For the           For the
                                                Three Months      Three Months
                                                Ended             Ended
                                                February 29,      February 28,
                                                   2008              2007

    Revenue                                  $     751,788     $   1,728,676

    Cost of revenue                                330,741           731,099

    Gross profit                                   421,047           997,577

    Selling, general and administrative
     expenses                                    1,844,056         2,224,207
    Research and development expenses               60,203           427,795


    Loss from continuing operations             (1,483,212)       (1,654,425)


    Interest expense                                (7,660)           (7,979)
    Interest income                                  6,264           100,902
    Loss from operations of joint venture                -           (18,146)
    Other (expense) income                             (44)        1,975,400

    (Loss) income before income tax
     provision and discontinued operations      (1,484,652)          395,752

         Provision for income taxes                 (1,717)           (5,733)

    (Loss) income before discontinued
     operations                                 (1,486,369)          390,019

    Discontinued Operations:
      Income (Loss) from operations                487,185        (1,447,795)


    Net loss                                 $    (999,184)    $  (1,057,776)

    Basic (loss) income per share
      Weighted average shares outstanding       17,020,959        16,892,163

      Basic (loss) income per share --
       continuing operations                 $        (.09)    $         .02

      Basic income (loss) per share --
       discontinued operations                         .03              (.08)

      Basic (loss) income per share          $        (.06)    $        (.06)

    Diluted (loss) income per share
      Weighted average shares outstanding       17,020,959        17,997,358

      Diluted (loss) income per share --
       continuing operations                 $        (.09)    $         .02

      Diluted income (loss) per share --
       discontinued operations                         .03              (.08)

      Diluted (loss) income per share        $        (.06)    $        (.06)

Source: QMed, Inc.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.